Archive:Muscle Blaze: Difference between revisions

removed promotional stuf
No edit summary
Line 45: Line 45:
In 2024, Muscle Blaze, under its parent company Bright Lifecare Private Limited, developed an Potentiated Ashwagandha roots compound with improved efficacy. The formulation was designed to provide a full spectrum of active constituents from ashwagandha roots, with the aim of enhancing its intended biological effects for consumers. The innovation was subsequently granted a patent.<ref>{{cite web |last1=Trehan |first1=Anupam |last2=Verma |first2=Manoj Kumar |last3=Gupta |first3=Anurag |last4=Anand |first4=Rachna |last5=Taneja |first5=Gopal |last6=Maheshwari |first6=Sameer |title=Potentiated Ashwagandha roots compound with Improved Efficacy |url=https://patents.google.com/patent/US20250099527A1/en?q=(bright+lifecare+pvt)&assignee=Bright+Lifecare+Pvt.+Ltd |date=27 March 2025}}</ref>
In 2024, Muscle Blaze, under its parent company Bright Lifecare Private Limited, developed an Potentiated Ashwagandha roots compound with improved efficacy. The formulation was designed to provide a full spectrum of active constituents from ashwagandha roots, with the aim of enhancing its intended biological effects for consumers. The innovation was subsequently granted a patent.<ref>{{cite web |last1=Trehan |first1=Anupam |last2=Verma |first2=Manoj Kumar |last3=Gupta |first3=Anurag |last4=Anand |first4=Rachna |last5=Taneja |first5=Gopal |last6=Maheshwari |first6=Sameer |title=Potentiated Ashwagandha roots compound with Improved Efficacy |url=https://patents.google.com/patent/US20250099527A1/en?q=(bright+lifecare+pvt)&assignee=Bright+Lifecare+Pvt.+Ltd |date=27 March 2025}}</ref>


Muscle Blaze sponsored and published a clinical study evaluating its proprietary MB CreAmp (creatine monohydrate) formulation against conventional creatine monohydrate. The randomized clinical trial involved 32 healthy male volunteers. According to the company's published findings, MB CreAmp demonstrated higher bioavailability, improved absorption, and greater plasma retention compared with conventional creatine monohydrate.<ref name="Trehan-2025"/>
Muscle Blaze published a clinical study evaluating its proprietary MB CreAmp (creatine monohydrate) formulation against conventional creatine monohydrate. The randomized clinical trial involved 32 healthy male volunteers. According to the company's published findings, MB CreAmp demonstrated higher bioavailability, improved absorption, and greater plasma retention compared with conventional creatine monohydrate.<ref name="Trehan-2025"/>


== Filmography ==
== Filmography ==